ADMA Quote, Financials, Valuation and Earnings

Aldeyra Therapeutics, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of --. ADMA Biologics, Inc.'s return on equity of 58.71% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.

ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 31.09%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 94.89%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than ADMA Biologics, Inc..

ADMA Biologics, Inc. has a beta of 0.433, which suggesting that the stock is 56.749% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.

ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.

ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. ADMA Biologics, Inc.'s net income of $36.4M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 22.99x while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 9.86x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Arcutis Biotherapeutics, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of 7.47%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.

ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 31.09%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 12.91%. Given that ADMA Biologics, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Arcutis Biotherapeutics, Inc..

ADMA Biologics, Inc. has a beta of 0.433, which suggesting that the stock is 56.749% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.345%.

ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. ADMA Biologics, Inc.'s net income of $36.4M is higher than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 22.99x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 9.86x versus 11.25x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Exelixis, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of 32.38%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Exelixis, Inc.'s return on equity of 31.26%.

ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 31.09%. On the other hand Exelixis, Inc. has an analysts' consensus of $45.28 which suggests that it could grow by 2.21%. Given that ADMA Biologics, Inc. has higher upside potential than Exelixis, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Exelixis, Inc..

ADMA Biologics, Inc. has a beta of 0.433, which suggesting that the stock is 56.749% less volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.400, suggesting its less volatile than the S&P 500 by 59.967%.

ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.

ADMA Biologics, Inc. quarterly revenues are $134.2M, which are smaller than Exelixis, Inc. quarterly revenues of $597.8M. ADMA Biologics, Inc.'s net income of $36.4M is lower than Exelixis, Inc.'s net income of $193.6M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 22.99x while Exelixis, Inc.'s PE ratio is 18.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 9.86x versus 5.54x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of -40.15%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 31.09%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 74.07%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than ADMA Biologics, Inc..

ADMA Biologics, Inc. has a beta of 0.433, which suggesting that the stock is 56.749% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.

ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. ADMA Biologics, Inc.'s net income of $36.4M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 22.99x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 9.86x versus 1.87x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.